HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van de Putte, L B A Articles by Kupper, H Search for Related Content PubMed PubMed Citation Articles by van de Putte, L B A Articles by Kupper, H

Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

¹ University Hospital Nijmegen, Nijmegen, The Netherlands
² Rheumaklinik, Ratingen, Germany
³ University of Leiden, Leiden, The Netherlands
⁴ University of Erlangen, Erlangen, Germany
⁵ University Hospital Liège, Liège, Belgium
⁶ Universität München, München, Germany
⁷ University of Leeds, Leeds, UK
⁸ Universitätsklinikum Charité, Berlin, Germany
⁹ Medizinische Hochschule Hannover, Hannover, Germany
¹⁰ National and Kapodistrian University, Athens, Greece
¹¹ Abbott GmbH & Co. KG, Ludwigshafen, Germany

Correspondence to:
Correspondence to:
Professor L B A van de Putte
University Medical Centre Nijmegen, Department of Rheumatology, PO Box 9101, 6500 HB Nijmegen, The Netherlands; annrheumdis.edoff{at}worldonline.nl

Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA).

Methods: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs.

Results: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures. ACR20 responses with adalimumab were significant at each assessment versus placebo (p0.01). Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively, versus 10.0% for placebo (p0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%, respectively, versus 1.4% for placebo (p0.001 for all comparisons); and ACR70 rates were 11.3%, 10.0%, and 8.3%, respectively, versus 0.0% for placebo (p0.05 for all comparisons). All adalimumab doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo.

Conclusions: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects.

Keywords: adalimumab; monoclonal antibodies; tumour necrosis factor ; rheumatoid arthritis; disease modifying antirheumatic drugs

Abbreviations: ACR, American College of Rheumatology; AEs, adverse events; ANAs, antinuclear antibodies; ANCOVA, analysis of covariance; CRP, C reactive protein; CTC, Common Toxicity Criteria; DAS, disease activity score; DMARDs, disease modifying antirheumatic drugs; dsDNA, double stranded DNA; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; ITT, intention to treat; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; sc, subcutaneously; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor

This article has been cited by other articles:

				Y. Yazici, N. M. Adler, and H. Yazici Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations Rheumatology, July 1, 2008; 47(7): 1054 - 1057. [Abstract] [Full Text] [PDF]

				D Aletaha, V Strand, J S Smolen, and M M Ward Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results Ann Rheum Dis, February 1, 2008; 67(2): 238 - 243. [Abstract] [Full Text] [PDF]

				W Kievit, J Fransen, A J M Oerlemans, H H Kuper, M A F J van der Laar, D J R A M de Rooij, C M A De Gendt, K H Ronday, T L Jansen, P C M van Oijen, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice Ann Rheum Dis, November 1, 2007; 66(11): 1473 - 1478. [Abstract] [Full Text] [PDF]

				W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut, September 1, 2007; 56(9): 1232 - 1239. [Abstract] [Full Text] [PDF]

				Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]

				R M Fleischmann, J Tesser, M H Schiff, J Schechtman, G-R Burmester, R Bennett, D Modafferi, L Zhou, D Bell, and B Appleton Safety of extended treatment with anakinra in patients with rheumatoid arthritis Ann Rheum Dis, August 1, 2006; 65(8): 1006 - 1012. [Abstract] [Full Text] [PDF]

				T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, May 17, 2006; 295(19): 2275 - 2285. [Abstract] [Full Text] [PDF]

				D Aletaha and M M Ward Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials Ann Rheum Dis, February 1, 2006; 65(2): 227 - 233. [Abstract] [Full Text] [PDF]

				A Kavanaugh Health economics: implications for novel antirheumatic therapies Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv65 - iv69. [Abstract] [Full Text] [PDF]

				N J Bansback, A Brennan, and O Ghatnekar Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Ann Rheum Dis, July 1, 2005; 64(7): 995 - 1002. [Abstract] [Full Text] [PDF]

				P Mease TNF{alpha} therapy in psoriatic arthritis and psoriasis Ann Rheum Dis, July 1, 2004; 63(7): 755 - 758. [Full Text] [PDF]

				L B A van de Putte, C Atkins, M Malaise, J Sany, A S Russell, P L C M van Riel, L Settas, J W Bijlsma, S Todesco, M Dougados, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis, May 1, 2004; 63(5): 508 - 516. [Abstract] [Full Text] [PDF]